Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Batten Disease - Pipeline Review, H1 2019, provides an overview of the Batten Disease (Central Nervous System) pipeline landscape.
Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known as the neuronal ceroid lipofuscinoses. Symptoms of Batten disease usually become apparent between five and 15 years of age. Symptoms include vision loss, lack of muscle coordination, mental retardation or decreasing mental function, emotional disturbances, seizures, muscle spasms, deterioration of muscle tone and movement problems.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Batten Disease - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Batten Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Batten Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Batten Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 16 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively.
Batten Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Batten Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Batten Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Batten Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Batten Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Batten Disease (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Batten Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Batten Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Batten Disease - Overview
Batten Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Batten Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Batten Disease - Companies Involved in Therapeutics Development
Abeona Therapeutics Inc
Amicus Therapeutics Inc
Exicure Inc
Recursion Pharmaceuticals Inc
RegenxBio Inc
Spark Therapeutics Inc
Batten Disease - Drug Profiles
(gemfibrozil + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABO-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABO-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Activate CLN6 for Batten Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUOC-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gemfibrozil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate CLN1 for Batten Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate CLN3 for Batten Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate CLN6 for Batten Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate CLN8 for Batten Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Palmitoyl Protein Thioesterase 1 for Batten Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate TPP1 for Batten Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Tripeptidyl Peptidase 1 for Batten Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INI-0602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Palmitoyl-Protein Thioesterase-1 Replacement for Batten Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGX-181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Batten Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Batten Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Batten Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDC42 for Batten Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNB-4050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPKTPP-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Batten Disease - Dormant Projects
Batten Disease - Discontinued Products
Batten Disease - Product Development Milestones
Featured News & Press Releases
Jan 31, 2019: Spark Therapeutics announces presentation of preclinical data in CLN2 disease at 15th annual WORLDSymposium
Jan 31, 2019: REGENXBIO receives Rare Pediatric Disease Designation for RGX-181 Gene Therapy for the Treatment of CLN2 Form of Batten Disease
Dec 06, 2018: Abeona Therapeutics provides update on Infantile Batten Disease drug candidate ABO-202 at 2018 R&D Day
Nov 14, 2018: FDA grants Orphan Drug Designation to RGX-181 gene therapy for the treatment of CLN2 form of Batten disease
Aug 30, 2018: REGENXBIO Announces Pipeline Expansion With RGX-181 Gene Therapy For CLN2 Form Of Batten Disease
Apr 20, 2018: Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
Mar 15, 2018: Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease
Feb 12, 2018: Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease
Dec 11, 2017: Polaryx Therapeutics Receives Orphan Drug Designation From the US FDA for the Treatment of Neuronal Ceroid Lipofuscinoses With PLX-100
Aug 07, 2017: Polaryx Therapeutics Receives Orphan Drug Designation From the U.S. FDA for PLX-200
Feb 07, 2017: Abeona Therapeutics Presents Data on ABO-201 at the 13th Annual WORLDSymposium 2017
Feb 07, 2017: Abeona Therapeutics Presents Data on ABO-202 at the 13th Annual WORLDSymposium 2017
Jan 03, 2017: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-201 Gene Therapy Program in Juvenile Batten Disease
Oct 07, 2016: Abeona Therapeutics Announces Publication of Preclinical Data Supporting Clinical Translation of Juvenile Batten Disease Gene Therapy
Mar 02, 2016: Abeona Therapeutics Highlights New Preclinical Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) Data at WORLDSymposium 2016
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Batten Disease, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Batten Disease - Pipeline by Abeona Therapeutics Inc, H1 2019
Batten Disease - Pipeline by Amicus Therapeutics Inc, H1 2019
Batten Disease - Pipeline by Exicure Inc, H1 2019
Batten Disease - Pipeline by Recursion Pharmaceuticals Inc, H1 2019
Batten Disease - Pipeline by RegenxBio Inc, H1 2019
Batten Disease - Pipeline by Spark Therapeutics Inc, H1 2019
Batten Disease - Dormant Projects, H1 2019
Batten Disease - Discontinued Products, H1 2019
List of Figures
Number of Products under Development for Batten Disease, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Top 10 Routes of Administration, H1 2019
Number of Products by Stage and Top 10 Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
